

Wisconsin Division of Public Health Newborn Screening Advisory Metabolic Subcommittee Meeting

Friday, October 13, 2017 WI State Lab of Hygiene – Ag Drive 10am – 2pm Minutes

| Me | Meeting Attendees: | | | | |
|----|--------------------|---|-------------------|---|-----------------------------|
| Χ | Dr. Mei Baker | Χ | Dr. Gary Kirk | Х | Dr. Greg Rice |
| | Linda Beischel | Χ | Jessica Kopesky | Х | Dana Schippman |
| Х | Beth Beyer | | Jessica Krause | Χ | Dr. Jessica Scott-Schwoerer |
| Х | Therese Breunig | Χ | Ashley Kuhl | Χ | Dr. Robert Steiner |
| | Erin Cronn | | Gina Lewis | | Vicky Tiberi |
| Х | Nicoletta Drillias | | Haley Lynn | Χ | Tammi Timmler |
| Х | Dr. Patrice Held | Χ | Emily Moe | | Erica Walters |
| Х | Sonja Henry | | Lisa Obernalte | Χ | Amy White |
| Х | Tami Horzewski | Χ | Stephanie Offord | | Dr. Samuel Yang |
| Х | Kate Johnson | Χ | Matt Rasberry | | Linda Yim-Drouin |
| | | Χ | Dr. William Rhead | | |



Wisconsin Division of Public Health Newborn Screening Advisory Metabolic Subcommittee Meeting

Friday, October 13, 2017 WI State Lab of Hygiene – Ag Drive 10am – 2pm Minutes

Purpose of Meeting:

The Metabolic Subcommittee serves in an advisory capacity to the Umbrella Committee and NBS Program regarding the specific screening-related condition(s) in the following areas:

Expert Knowledge in Condition-Specific Clinical Care and Research

• Advises on condition-specific clinical care including ongoing changes in treatment options for affected individuals, emerging newborn screening technology, and condition-specific research.

Quality Assurance

- Reviews de-identified screening and confirmatory testing data to monitor screening test performance, such as screening positive predictive value, screening false positive rate and false negative rate.
- Recommends changes in NBS practice to the Umbrella Committee and NBS Program.

Education for Families and Providers

• Reviews and provides feedback on information and education materials for general public, families, and providers to assure accuracy of health information related to the specific condition(s).

Addition/Deletion of Conditions

Recommends and/or reviews nominations for addition and deletion of conditions related to the subcommittee

| | Facilitator/Chair | r:Dr. Greg Rice | Recorder:Tam | i Horzewski |
|------------------------------|-------------------------------|---|--|--|
| Info Decision Discuss. | Time: | Topic(s) | Follow-up Items Decision/action: Name: Date due: | Content-focused minutes |
| Info | 10:00 - 2:00 (Lunch 12:00) | Welcome and Introductions (Dr. Rice (Chair)) Review and Approve Minutes | | Motion to approve the Minutes 1st motion Dr. Mei Baker 2nd motion Dr. Scott-Schwoerer Motion to approve minutes from Jan 27, 2017. Accepted. |



| Info | Department of Health Services (DHS) Updates (Kirk) | The Birth Defects registry is now opt out. Suggested to look at NBS conditions that are on the Birth Defects Registry. Welcome Dr. Gary Kirk, new Chief Medical Officer, Bureau of Community Health Promotion, Department of Health Services. |
|-----------|--|--|
| Info/Disc | Krabbe Literature Review (Rice/All) | Dr. Rice welcomed the Cushman family and friends. The subcommittee discussed a review of current Krabbe literature. A recent article was less convincing, showing a 10% increase in mortality associated with the treatment. The subcommittee will continue to be vigilant of new Krabbe literature and will do a reevaluation when the condition is again reviewed at the national level. |
| | Update SACNBS recommendation on CPT IA (Rice) | The Secretary's Advisory Committee on Newborn Screening met on October 12, 2017. The committee recommended the addition of CPT IA to the WI Newborn Screening Panel of Conditions. A written report with the committee's recommendation will be sent to the Secretary of the Department of Health Services for a final decision. The timeline for the Secretary's decision is unknown at this time. |



| Info | | Pompe Screening Update & clinical follow-up of the new Pompe babies identified since the pilot started (Dr. Baker/Dr. Rhead) | Determine which standard tool to use for psychosocial assessment at the clinics. | Mei reviewed the current screening process: All the specimens undergo a 6-plex enzyme activity measurement assay. If the situation of GAA activity is less than 15% of the daily median, the lab will review the other 5 enzymes' activities (ASM- Niemann–Pick disease, GLA- Fabry disease, IDUA- MPS I, ABG-Gaucher disease, and GALC- Krabbe disease). With one or more additional enzyme activity lower than 15% of the daily median, the specimen will be deemed as unsatisfactory. All specimens undergo CLIR assessment. Specimens with GAA 10-15% of daily median are reported as possible abnormal Specimens will undergo GAA gene sequencing assay and are sent to Mayo for the second tier testing (PD2T) when GAA is lower than 10% daily median, and/ or there are indications of likely Pompe by CLIR. The lab will communicate the GAA enzyme and PD2T results to the PCP and a metabolic physician. GAA gene sequencing results are usually available within one week Mei also provided the following Pompe screening summary for the screening period between 7/14/17 to 10/7/17. |
|------|--|--|--|---|
|------|--|--|--|---|





| | | (NIH) data collection ar NewSTEPs data entry if follow-up data element Pompe NBS pilot team follow-up data elements GAA Gene Sequencin | g Report Based on the feedbac ne lab will include variant catego | e hort-term vith the ort-term k from the |
|------|---|--|---|---|
| | | | Pompe Center Classification | ClinVar |
| | | | | |
| | | | Potentially Mild | Pathoge |
| | | | Very severe | Likely Pa |
| Info | Disclaimer language – variation in age/timing of screening (Dr. Baker/Dr. Held) | Baker) As a result of discussion children beyond the new disclaimer to be included approved the disclaimer. The screening tests performed newborns. Reference established within the more sult should not be used showing clinical signs of the stables. | Variation in Age/timing of Screen on how to handle "NBS" requewborn period, the lab has develowd in the report. The group review language as below. If the specimen were interest and the specimen were interest as the specimen were interest as the specimen were interest. If the newborn is a symptoms of a disease on the gnostic assessment is recommend. | sts for ped a wed and antended port were test s screening |
| | Working Lunch | | | |



| Discuss | Review of Testing/Cutoffs for SCHADD/Malonic Acidemia (Dr. Held) | Dr. Held reported to the committee two failed PT challenges for the analyte C4OH/C3DC. Both failed challenges were due to cutoff being set too high (8 standard deviations from mean). The laboratory asked the committee to consider lowering cutoff to be able to achieve a passing score on the PT specimens. However, the committee felt that more information was needed and decided to remain the current cutoff (3.03uM). Motion to leave the current cutoff as is. First motion – Greg Rice. Second motion – Bob Steiner. The laboratory will consult with CDC, review data from the one confirmed Wisconsin case (malonic acidemia), and consult with other states and possibly obtain DBS punches from other confirmed cases to evaluate. |
|---------|--|---|
| Discuss | Review of Testing/Cutoffs for Carnitine Uptake Deficiency (Dr. Held) | Dr Held reported a large number of false positives for CUD. In two years, 170 had an initial abnormal CUD profile. 142 of the 170 had a normal repeat specimen. 28 of the 170 had an abnormal repeat specimen, consistent with CUD and were referred for confirmatory testing. Confirmatory testing revealed 1 CUD case, 6 cases of maternal CUD, 20 false positives, and 1 still pending. The committee agreed to review the testing algorithm to reduce the number of false positives. The laboratory will consider the impact of prematurity and whether there is an increased false positive rate amongst babies in the NICU. Additionally, the laboratory will review whether any of the false positive cases were actually maternal CUD. |
| Discuss | Review of Testing/Cutoffs for 3-MCC/3-MGA/MCD (Dr. Held) | Dr. Held reported an increased number of referrals for elevated C5OH over the past three years, with majority being false positives. Of the 12 confirmed cases from 2015-2017, all but one were from MCW. The committee discussed how cases were determined to true cases or false positives. MCW agreed to review their data on confirmed cases. Dr. Held will review region 4 database for more comparison information regarding cutoffs. |



Wisconsin Division of Public Health Newborn Screening Advisory Metabolic Subcommittee Meeting Friday, October 13, 2017

Friday, October 13, 2017 WI State Lab of Hygiene – Ag Drive 10am – 2pm Minutes

| Discuss | Clinical Formula Pledge and Proof of Residency (Rasberry) | Matt Rasberry, UW-Waisman Center, shared a Clinical Formula Pledge form for review by the committee. The committee agreed that the use of the form is beneficial. Matt will make slight changes to the draft form. |
|---------|--|--|
| | Plan Next Meeting/Agenda Items | Tami will send out a doodle poll for the scheduling of the next metabolic subcommittee meeting. No agenda items for the next meeting mentioned at the time of the meeting. |

"Parking Lot" Items: